DeliriumDLANCT01274819
Dynamic Light Application to Prevent ICU Acquired Delirium
A study testing Dynamic Light in people with Delirium and Confusion, run by Jeroen Bosch Ziekenhuis at 1 site in Netherlands.
Trial summary
Rationale: Delirium is a frequently encountered problem in ICU patients and leads to increased morbidity and mortality; Delirium in the ICU is associated with sleep deprivation which is among others caused by a disrupted circadian rhythm; Dynamic Light application aims at restoring a proper circadian rhythm by… Read more about this study
- Who is it for?
- Ages 18 years and older
- What is being tested?
- Dynamic Light
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,000 participants
- Where
- 1 siteNetherlands
- Study dates
- Jul 2011to Sep 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ICU-patients >18 yrs old
- expected duration of stay > 24 hrs
Who cannot join
- life expectancy of <48 hrs on ICU admission
- necessity of prolonged deep sedation
- blindness
- inability to speak or understand dutch
Trial locations and contacts
1 site in 1 country.
About this study
Rationale: Delirium is a frequently encountered problem in ICU patients and leads to increased morbidity and mortality; Delirium in the ICU is associated with sleep deprivation which is among others caused by a disrupted circadian rhythm; Dynamic Light application aims at restoring a proper circadian rhythm by rhythmically alternating light intensity and has shown beneficial effects in sleep quality. Whether DLA improves sleep quality and reduces delirium incidence in ICU patients is not known
Goals/endpoints:
Read more
To evaluate the feasibility of dynamic light application in the ICU and to study the effects of dynamic light application on the incidence of delirium, duration of mechanical ventilation, the number of ICU and hospital days, and mortality in a mixed population of medical and surgical ICU patients. In a subgroup of patients with a high risk of developing delirium, markers of circadian rhythm, inflammation and brain damage and post ICU HRQoL will be assessed Study design: prospective randomized single centre trial Study population: adult ICU patients > 18 years old with an expected duration of stay of more than 24 hours Intervention: Patients will be randomized between Standard Care or Standard Care + DLA; When receiving standard care, normal lighting settings will be used in that patient room, which can be controlled by the medical personnel; In the rooms of patients randomized to the DLA group, DL is applied with a changing intensity during the day according to a fixed rhythm, which is regulated centrally. In addition when necessary, an intervention light can be used which can be operated in the patient room.
Study parameters/endpoints: incidence of delirium as measured by the CAM-ICU; duration of mechanical ventilation, ICU and total hospital mortality; ICU and hospital LOS; Serum levels of inflammatory markers and markers of brain damage, urinary levels of markers of circadian rhythm, data of HRQoL questionnaires and total light exposure in both groups
Read the detailed description
STUDY DESIGN This is a prospective randomized, single centre trial. The proposed starting date is 01-july- 2011 and the duration of the study will be 15 months.
All ICU patients who are expected to have an ICU stay of more than 24 hours are potential eligible. On ICU admission, patients will be screened for eligibility. The patients' demographics, patients' health status, medication use, APACHE II score, SOFA score and admission diagnosis will be reported at baseline. Before recruitment and enrollment in the study, each patient and/or relative will be given full explanation of the study and will be informed that they are free to discontinue their participation in the study at any time.
When considered eligible, patients will be given a unique patient number in consecutive order and will be assigned to the treatment corresponding with this number. Patients will be randomized in a one-on-one fashion according to a computer generated randomization list between Standard Care and Standard Care + DLA. The randomization list will be kept at the data co-ordination centre.
All of the 20 patient rooms on the 2 ICU wards are equipped with a special lighting system. This lighting system can offer the standard basic lighting in the patient room, with a set intensity and light colour, or the DL setting which offers changing light conditions depending on the time of the day, following a rhythmic pattern. In addition, all rooms have a basic low-intensity orientation light, which is turned on during night-time in all rooms.
The switch between the two modes is regulated centrally on a control panel that is located in the nursing station and cannot be altered in the patient-room
1.1 Standard Care On admission, a full physical examination is performed and, when possible, a history taken. An ECG and chest x-ray, when not performed shortly before, will be done. In addition, blood will be drawn from the indwelling arterial catheter for haemoglobin, leucocyte and thrombocyte count, renal and liver function, electrolytes, arterial blood gas analysis, lactate and markers of inflammation (C-reactive protein, procalcitonin). Blood pressure, heart rate, fluid balance, oxygen saturation are measured continuously and automatically registered in our Patient Data Management System (PDMS). When considered necessary, ventilatory support is commenced or continued (post-operative patients) and additional hemodynamic measurements performed.
All patients will receive thromboprophylaxis, when no clear contraindications exist, and ulcer prophylaxis. When patients are intubated, they receive analgesic and often sedative medications for patient comfort. If patients are expected to receive mechanical ventilation for at least 48 hours, Selective Digestive Decontamination (SDD) prophylaxis is commenced, consisting of application of oral and gastrointestinal antibiotic suspension, administration of four days of i.v. antibiotics (cefotaxime) and surveillance cultures.
Twice daily at 0800hrs and 2000hrs, routine blood analysis consisting of arterial blood gas analysis, haemoglobin, leucocyte and thrombocyte electrolytes, renal function and markers of inflammation, is performed. When no clear contraindications exist, sedative infusions are interrupted every morning since this has proven to decrease length of mechanical ventilation (39). In addition, when considered feasible, an attempt is made to "wean" the patient off the mechanical ventilator. Protocol-guided early mobilisation is commenced as soon as possible, directed by dedicated physical therapists.
Level of sedation is monitored as part of daily care by nurses in all patients every two hours using the Richmond Agitation Sedation Scale (RASS). This scale divides levels of consciousness indicated by a number ranging from -5 (unarousable) to +4 (combative, see Appendix). Ideally, patients have a RASS of 0 (alert and calm) and sedation is titrated to achieve a RASS of -2 to 0. In addition, screening on the presence of delirium is done using the CAM-ICU every eight hours by well trained ICU nurses . As has been mentioned before, this method has been validated for use in ICU patients and is easy to use by non-psychiatric personnel. When the CAM-ICU is positive, delirium treatment is started according to our protocol (see Appendix).
Standard measures to prevent delirium among our patients include maintaining a proper day-and- night rhythm by promoting night-time sleep (reduction of light and noise disturbance and reduction of daytime sleep using daily activity programs and mobilisation. When patients have visual or auditive impairments, glasses and hearing aids are being used as much as possible. A clock is present in each ICU room and relatives are asked to bring photographs of them so that patients can have some sense of familiarity. Dosages of deliriogenic medications (anticholinergics, opiates, benzodiazepines) are reduced as much as possible however cannot be ruled out completely since benzodiazepines and opiates are often used for sedation and analgesia.
When a patient is randomized to receive the basic light setting, standard lighting is used, including the possibility of using a high intensity intervention light when performing interventions. The light switch in the room then offers three options: 1) main light on 2) main light off 3) intervention light on/off.
1.2 Standard Care + DLA In addition to standard care, inpatients who are randomized at receiving DLA, the light switch in that room is set to DLA, as soon as possible after the patient is installed and initial investigation and handlings (e.g. placing urinary catheter, a central venous line and/or arterial cannula) have been performed. When interventions are necessary, a high intensity intervention light can be turned on manually by physicians or nurses. The lighting operation panel in this room then offers only one option, i.e. intervention light on/off. A computer will log the use of the dynamic lighting system,
1.3 Assessment During the first 24 hours, the risk of developing delirium will be assessed using the validated PRE-DELIRIC score. When patients with have a risk of developing delirium ≥>40%, they will be defined as a high risk patient.
In all patients, the presence of delirium is assessed three times a day until death or discharge off the ICU or death on fixed times using the CAM-ICU. When patients are unconscious, either because of their illness or due to sedative medications, the CAM-ICU cannot be performed and delirium cannot be assessed. This will be recorded in the case-record form.
Since delirium is associated with the use of sedatives and opioids, 24-hour dosages of these medications will be recorded daily at 8 am. For a list of these medications, see appendix.
In addition, renal function, (plasma creatinine and urea), electrolytes (sodium, potassium, ionized calcium) haemoglobin, white blood cell count, procalcitonin) will be monitored daily until discharge of the ICU. Total hospital length of stay will be registered for all patients. Patients will be analyzed in an intention-to-treat principle.
To assess differences in light exposure between the two groups, light levels are measured in every patient room, close to the patient's head. Since daylight may also influence total light exposure and differences exist in daylight exposure of the different patient rooms (See appendix 3) differences between light exposures in different rooms will be analysed and associated to the primary endpoint.
In patients with a high risk of developing delirium 5 ml of blood will be drawn on day 1,3,5,7, 14,21 and 28 and will be stored at -80 degrees Celsius until analysis. In addition in these high risk patients, circadian rhythm derived biomarkers will be determined by means of urinary excretion collected in 3-hour urinary samples during 24 hours on day 7, 14,21, 28 and then once per 2 weeks. To determine pre-existent quality of life a validated Health Related Quality of Life questionnaire will be used.
1.4 randomisation, blinding and allocation of treatment Patients will be randomized in one-on one fashion according to a computer generated randomization list. The randomization list will be kept at the data co-ordination centre. Since blinding is impossible with dynamic light, patients and relatives, nurses and doctors are aware of the treatment arm.
1.5 Study procedures DLA will be applied in the DLA group. In all patients 5 ml of blood will be drawn within 24 hours after admission and stored. In high risk patients, an extra 5 ml of blood will be collected during the morning laboratory rounds on day 1, 3, 5, 7, 14, 21 and 28. Since all patients have an indwelling arterial line and blood is already collected this is not considered to be an additional burden for the patient. In total a maximum of ca. 35 millilitres of blood during a period of 28 days will be collected. In addition in high risk patients, 3 -hour urinary samples will be collected during 24 hours on day 7, 14, 21, 28 and than every week until discharge off the ICU. On our ICU, all patients have an indwelling urinary catheter. On admission, a validated QoL questionnaire will be handed over to the patient or his/her next of kin to determine the pre-existent QoL; after 3, 6 and 12 months a QoL questionnaire will be sent to the patient to determine the post ICU QoL.
Analysis will be performed on the whole group but also in a post-hoc analysis where the effect of DLA will be analysed per season of admission.
- Being tested
- Dynamic Light
- Keywords
- delirium, confusion
- Medical subject headings
- Delirium, Confusion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dynamic LightOther
Also called Philips
Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
| Study group | Role | What they receive |
|---|---|---|
| Dynamic light | Experimental | ICU patients exposed to dynamic light during ICU stay Receives: Other: Dynamic Light |
| Normal Light | No intervention | control group is exposed to normal light during ICU stay |
What is being measured
The primary outcome is the main question the study is designed to answer.
delirium outcome
This is a composite endpoint of incidence of delirium during ICU stay, 28-day delirium free days (28-DFD) and 28-day ventilator free days (28-VFD)
Measured: duration of ICU stay(average duration 5 days)
Secondary outcomes (7)
ICU length-of-stay and ICU mortality
ICU length-of-stay and ICU mortality
Measured: duration of ICU stay, (average duration 5 days)
duration of mechanical ventilation
Measured: duration of ICU stay (average duration 5 days)
Hospital length-of-stay and hospital mortality
Measured: duration of hospital stay (average duration 14 days)
serum levels of inflammatory markers and markers of brain damage
when patients are considered to be at high risk of developing ICU acquired delirium ( using a validated scoring system) blood samples will be drawn on days 1, 3, 5, 7, 14, 21, and 28 after inclusion in the study and stored at -80 degrees until analysis.
Measured: duration of ICU stay (average duration 5 days)
urinary levels of markers of circadian rhythm
in a subgroup of long-stay ICU patients 3-hour urinary samples of cortisol and melatonin will taken during 24 hours to determine the circadian rhythm and the possible effect of DLA on this rhythm
Measured: duration of ICU stay (average duration 5 days)
data of Health-related Quality of Life (HrQoL) questionnaires
3 and 6 months after ICU discharge, a validated HrQoL will be sent to patients homes to assess their QoL after the ICU stay and to detect differences between the DLA and reference group
Measured: during ICU stay and 3, 6 and 12 months after ICU discharge
Delirium-free days without coma in 28 days
To assess whether Dynamic Light not only influences incidence of delirium, but also duration of delirium, 28-day delirium free days without coma is used as a marker of duration of delirium. Patients who leave the ICU with a delirium (defined as a positive CAM-ICU score within 3 days of ICU discharge) will be followed on the wards using nurse charts and the delirium observation scale (DOS) to assess duration of delirium after ICU discharge
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2011 (estimated)
- Study startJul 2011
- Primary completionSep 2013
- Study completionSep 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (41)Papers the sponsor has linked to this study.
- Other trials for DeliriumStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jeroen Bosch Ziekenhuis
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, K.S. Simons, Jeroen Bosch Ziekenhuis
- Investigators
- KS Simons, drs, Principal investigator, Jeroen Bosch Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01274819
- Sponsor's protocol ID
- DLA 2011
- Acronym
- DLA
- Status last verified
- Oct 2013
- First submitted
- 11 Jan 2011
- Last updated
- 16 Oct 2013
- Results posted
- No
- Data monitoring committee
- No
Publications
Peterson JF, Pun BT, Dittus RS, Thomason JW, Jackson JC, Shintani AK, Ely EW. Delirium and its motoric subtypes: a study of 614 critically ill patients. J Am Geriatr Soc. 2006 Mar;54(3):479-84. doi: 10.1111/j.1532-5415.2005.00621.x.
PubMed 16551316Ely EW, Gautam S, Margolin R, Francis J, May L, Speroff T, Truman B, Dittus R, Bernard R, Inouye SK. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med. 2001 Dec;27(12):1892-900. doi: 10.1007/s00134-001-1132-2. Epub 2001 Nov 8.
PubMed 11797025Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, Inouye SK, Bernard GR, Dittus RS. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004 Apr 14;291(14):1753-62. doi: 10.1001/jama.291.14.1753.
PubMed 15082703Thomason JW, Shintani A, Peterson JF, Pun BT, Jackson JC, Ely EW. Intensive care unit delirium is an independent predictor of longer hospital stay: a prospective analysis of 261 non-ventilated patients. Crit Care. 2005 Aug;9(4):R375-81. doi: 10.1186/cc3729. Epub 2005 Jun 1.
PubMed 16137350Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med. 2007 Jan;33(1):66-73. doi: 10.1007/s00134-006-0399-8. Epub 2006 Nov 11.
PubMed 17102966Pisani MA, Kong SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH. Days of delirium are associated with 1-year mortality in an older intensive care unit population. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1092-7. doi: 10.1164/rccm.200904-0537OC. Epub 2009 Sep 10.
PubMed 19745202Balas MC, Happ MB, Yang W, Chelluri L, Richmond T. Outcomes Associated With Delirium in Older Patients in Surgical ICUs. Chest. 2009 Jan;135(1):18-25. doi: 10.1378/chest.08-1456. Epub 2008 Nov 18.
PubMed 19017895Milbrandt EB, Deppen S, Harrison PL, Shintani AK, Speroff T, Stiles RA, Truman B, Bernard GR, Dittus RS, Ely EW. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004 Apr;32(4):955-62. doi: 10.1097/01.ccm.0000119429.16055.92.
PubMed 15071384Leslie DL, Marcantonio ER, Zhang Y, Leo-Summers L, Inouye SK. One-year health care costs associated with delirium in the elderly population. Arch Intern Med. 2008 Jan 14;168(1):27-32. doi: 10.1001/archinternmed.2007.4.
PubMed 18195192Devlin JW, Fong JJ, Howard EP, Skrobik Y, McCoy N, Yasuda C, Marshall J. Assessment of delirium in the intensive care unit: nursing practices and perceptions. Am J Crit Care. 2008 Nov;17(6):555-65; quiz 566.
PubMed 18978240Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, Cooney LM Jr. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999 Mar 4;340(9):669-76. doi: 10.1056/NEJM199903043400901.
PubMed 10053175Vidan MT, Sanchez E, Alonso M, Montero B, Ortiz J, Serra JA. An intervention integrated into daily clinical practice reduces the incidence of delirium during hospitalization in elderly patients. J Am Geriatr Soc. 2009 Nov;57(11):2029-36. doi: 10.1111/j.1532-5415.2009.02485.x. Epub 2009 Sep 15.
PubMed 19754498Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, Spears L, Miller M, Franczyk M, Deprizio D, Schmidt GA, Bowman A, Barr R, McCallister KE, Hall JB, Kress JP. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009 May 30;373(9678):1874-82. doi: 10.1016/S0140-6736(09)60658-9. Epub 2009 May 14.
PubMed 19446324Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009 Feb 4;301(5):489-99. doi: 10.1001/jama.2009.56. Epub 2009 Feb 2.
PubMed 19188334Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, Shintani AK, Thompson JL, Jackson JC, Deppen SA, Stiles RA, Dittus RS, Bernard GR, Ely EW. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007 Dec 12;298(22):2644-53. doi: 10.1001/jama.298.22.2644.
PubMed 18073360
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dynamic Light Application to Prevent ICU Acquired Delirium
- ClinicalTrials.gov ID
- NCT01274819
- Acronym / sponsor ID
- DLA / DLA 2011
- Keywords
- delirium, confusion
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- Jeroen Bosch ZiekenhuisUniversity, hospital or other
- Study start
- Jul 2011
- Primary completion
- Sep 2013 (actual)
- Study completion
- Sep 2013 (actual)
- First posted
- 12 Jan 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale: Delirium is a frequently encountered problem in ICU patients and leads to increased morbidity and mortality; Delirium in the ICU is associated with sleep deprivation which is among others caused by a disrupted circadian rhythm; Dynamic Light application aims at restoring a proper circadian rhythm by rhythmically alternating light intensity and has shown beneficial effects in sleep quality. Whether DLA improves sleep quality and reduces delirium incidence in ICU patients is not known
Goals/endpoints:
To evaluate the feasibility of dynamic light application in the ICU and to study the effects of dynamic light application on the incidence of delirium, duration of mechanical ventilation, the number of ICU and hospital days, and mortality in a mixed population of medical and surgical ICU patients. In a subgroup of patients with a high risk of developing delirium, markers of circadian rhythm, inflammation and brain damage and post ICU HRQoL will be assessed Study design: prospective randomized single centre trial Study population: adult ICU patients > 18 years old with an expected duration of stay of more than 24 hours Intervention: Patients will be randomized between Standard Care or Standard Care + DLA; When receiving standard care, normal lighting settings will be used in that patient room, which can be controlled by the medical personnel; In the rooms of patients randomized to the DLA group, DL is applied with a changing intensity during the day according to a fixed rhythm, which is regulated centrally. In addition when necessary, an intervention light can be used which can be operated in the patient room.
Study parameters/endpoints: incidence of delirium as measured by the CAM-ICU; duration of mechanical ventilation, ICU and total hospital mortality; ICU and hospital LOS; Serum levels of inflammatory markers and markers of brain damage, urinary levels of markers of circadian rhythm, data of HRQoL questionnaires and total light exposure in both groups
Detailed description
STUDY DESIGN This is a prospective randomized, single centre trial. The proposed starting date is 01-july- 2011 and the duration of the study will be 15 months.
All ICU patients who are expected to have an ICU stay of more than 24 hours are potential eligible. On ICU admission, patients will be screened for eligibility. The patients' demographics, patients' health status, medication use, APACHE II score, SOFA score and admission diagnosis will be reported at baseline. Before recruitment and enrollment in the study, each patient and/or relative will be given full explanation of the study and will be informed that they are free to discontinue their participation in the study at any time.
When considered eligible, patients will be given a unique patient number in consecutive order and will be assigned to the treatment corresponding with this number. Patients will be randomized in a one-on-one fashion according to a computer generated randomization list between Standard Care and Standard Care + DLA. The randomization list will be kept at the data co-ordination centre.
All of the 20 patient rooms on the 2 ICU wards are equipped with a special lighting system. This lighting system can offer the standard basic lighting in the patient room, with a set intensity and light colour, or the DL setting which offers changing light conditions depending on the time of the day, following a rhythmic pattern. In addition, all rooms have a basic low-intensity orientation light, which is turned on during night-time in all rooms.
The switch between the two modes is regulated centrally on a control panel that is located in the nursing station and cannot be altered in the patient-room
1.1 Standard Care On admission, a full physical examination is performed and, when possible, a history taken. An ECG and chest x-ray, when not performed shortly before, will be done. In addition, blood will be drawn from the indwelling arterial catheter for haemoglobin, leucocyte and thrombocyte count, renal and liver function, electrolytes, arterial blood gas analysis, lactate and markers of inflammation (C-reactive protein, procalcitonin). Blood pressure, heart rate, fluid balance, oxygen saturation are measured continuously and automatically registered in our Patient Data Management System (PDMS). When considered necessary, ventilatory support is commenced or continued (post-operative patients) and additional hemodynamic measurements performed.
All patients will receive thromboprophylaxis, when no clear contraindications exist, and ulcer prophylaxis. When patients are intubated, they receive analgesic and often sedative medications for patient comfort. If patients are expected to receive mechanical ventilation for at least 48 hours, Selective Digestive Decontamination (SDD) prophylaxis is commenced, consisting of application of oral and gastrointestinal antibiotic suspension, administration of four days of i.v. antibiotics (cefotaxime) and surveillance cultures.
Twice daily at 0800hrs and 2000hrs, routine blood analysis consisting of arterial blood gas analysis, haemoglobin, leucocyte and thrombocyte electrolytes, renal function and markers of inflammation, is performed. When no clear contraindications exist, sedative infusions are interrupted every morning since this has proven to decrease length of mechanical ventilation (39). In addition, when considered feasible, an attempt is made to "wean" the patient off the mechanical ventilator. Protocol-guided early mobilisation is commenced as soon as possible, directed by dedicated physical therapists.
Level of sedation is monitored as part of daily care by nurses in all patients every two hours using the Richmond Agitation Sedation Scale (RASS). This scale divides levels of consciousness indicated by a number ranging from -5 (unarousable) to +4 (combative, see Appendix). Ideally, patients have a RASS of 0 (alert and calm) and sedation is titrated to achieve a RASS of -2 to 0. In addition, screening on the presence of delirium is done using the CAM-ICU every eight hours by well trained ICU nurses . As has been mentioned before, this method has been validated for use in ICU patients and is easy to use by non-psychiatric personnel. When the CAM-ICU is positive, delirium treatment is started according to our protocol (see Appendix).
Standard measures to prevent delirium among our patients include maintaining a proper day-and- night rhythm by promoting night-time sleep (reduction of light and noise disturbance and reduction of daytime sleep using daily activity programs and mobilisation. When patients have visual or auditive impairments, glasses and hearing aids are being used as much as possible. A clock is present in each ICU room and relatives are asked to bring photographs of them so that patients can have some sense of familiarity. Dosages of deliriogenic medications (anticholinergics, opiates, benzodiazepines) are reduced as much as possible however cannot be ruled out completely since benzodiazepines and opiates are often used for sedation and analgesia.
When a patient is randomized to receive the basic light setting, standard lighting is used, including the possibility of using a high intensity intervention light when performing interventions. The light switch in the room then offers three options: 1) main light on 2) main light off 3) intervention light on/off.
1.2 Standard Care + DLA In addition to standard care, inpatients who are randomized at receiving DLA, the light switch in that room is set to DLA, as soon as possible after the patient is installed and initial investigation and handlings (e.g. placing urinary catheter, a central venous line and/or arterial cannula) have been performed. When interventions are necessary, a high intensity intervention light can be turned on manually by physicians or nurses. The lighting operation panel in this room then offers only one option, i.e. intervention light on/off. A computer will log the use of the dynamic lighting system,
1.3 Assessment During the first 24 hours, the risk of developing delirium will be assessed using the validated PRE-DELIRIC score. When patients with have a risk of developing delirium ≥>40%, they will be defined as a high risk patient.
In all patients, the presence of delirium is assessed three times a day until death or discharge off the ICU or death on fixed times using the CAM-ICU. When patients are unconscious, either because of their illness or due to sedative medications, the CAM-ICU cannot be performed and delirium cannot be assessed. This will be recorded in the case-record form.
Since delirium is associated with the use of sedatives and opioids, 24-hour dosages of these medications will be recorded daily at 8 am. For a list of these medications, see appendix.
In addition, renal function, (plasma creatinine and urea), electrolytes (sodium, potassium, ionized calcium) haemoglobin, white blood cell count, procalcitonin) will be monitored daily until discharge of the ICU. Total hospital length of stay will be registered for all patients. Patients will be analyzed in an intention-to-treat principle.
To assess differences in light exposure between the two groups, light levels are measured in every patient room, close to the patient's head. Since daylight may also influence total light exposure and differences exist in daylight exposure of the different patient rooms (See appendix 3) differences between light exposures in different rooms will be analysed and associated to the primary endpoint.
In patients with a high risk of developing delirium 5 ml of blood will be drawn on day 1,3,5,7, 14,21 and 28 and will be stored at -80 degrees Celsius until analysis. In addition in these high risk patients, circadian rhythm derived biomarkers will be determined by means of urinary excretion collected in 3-hour urinary samples during 24 hours on day 7, 14,21, 28 and then once per 2 weeks. To determine pre-existent quality of life a validated Health Related Quality of Life questionnaire will be used.
1.4 randomisation, blinding and allocation of treatment Patients will be randomized in one-on one fashion according to a computer generated randomization list. The randomization list will be kept at the data co-ordination centre. Since blinding is impossible with dynamic light, patients and relatives, nurses and doctors are aware of the treatment arm.
1.5 Study procedures DLA will be applied in the DLA group. In all patients 5 ml of blood will be drawn within 24 hours after admission and stored. In high risk patients, an extra 5 ml of blood will be collected during the morning laboratory rounds on day 1, 3, 5, 7, 14, 21 and 28. Since all patients have an indwelling arterial line and blood is already collected this is not considered to be an additional burden for the patient. In total a maximum of ca. 35 millilitres of blood during a period of 28 days will be collected. In addition in high risk patients, 3 -hour urinary samples will be collected during 24 hours on day 7, 14, 21, 28 and than every week until discharge off the ICU. On our ICU, all patients have an indwelling urinary catheter. On admission, a validated QoL questionnaire will be handed over to the patient or his/her next of kin to determine the pre-existent QoL; after 3, 6 and 12 months a QoL questionnaire will be sent to the patient to determine the post ICU QoL.
Analysis will be performed on the whole group but also in a post-hoc analysis where the effect of DLA will be analysed per season of admission.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dynamic light | Experimental | Other: Dynamic LightICU patients exposed to dynamic light during ICU stay |
| Normal Light | No intervention | –control group is exposed to normal light during ICU stay |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- ICU-patients >18 yrs old
- expected duration of stay > 24 hrs
Key exclusion criteria (4 listed)
- life expectancy of <48 hrs on ICU admission
- necessity of prolonged deep sedation
- blindness
- inability to speak or understand dutch
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dynamic LightAlso: PhilipsDynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure. | Other | Dynamic light |
Primary outcome
delirium outcome
Time frame: duration of ICU stay(average duration 5 days)
This is a composite endpoint of incidence of delirium during ICU stay, 28-day delirium free days (28-DFD) and 28-day ventilator free days (28-VFD)
7 secondary outcomes
ICU length-of-stay and ICU mortality
Time frame: duration of ICU stay, (average duration 5 days)
duration of mechanical ventilation
Time frame: duration of ICU stay (average duration 5 days)
Hospital length-of-stay and hospital mortality
Time frame: duration of hospital stay (average duration 14 days)
serum levels of inflammatory markers and markers of brain damage
Time frame: duration of ICU stay (average duration 5 days)
urinary levels of markers of circadian rhythm
Time frame: duration of ICU stay (average duration 5 days)
data of Health-related Quality of Life (HrQoL) questionnaires
Time frame: during ICU stay and 3, 6 and 12 months after ICU discharge
Delirium-free days without coma in 28 days
Time frame: 28 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2013.
- Background: PubMed 16551316Peterson JF, Pun BT, Dittus RS, Thomason JW, Jackson JC, Shintani AK, Ely EW. Delirium and its motoric subtypes: a study of 614 critically ill patients. J Am Geriatr Soc. 2006 Mar;54(3):479-84. doi: 10.1111/j.1532-5415.2005.00621.x.
- Background: PubMed 11797025Ely EW, Gautam S, Margolin R, Francis J, May L, Speroff T, Truman B, Dittus R, Bernard R, Inouye SK. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med. 2001 Dec;27(12):1892-900. doi: 10.1007/s00134-001-1132-2. Epub 2001 Nov 8.
- Background: PubMed 15082703Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, Inouye SK, Bernard GR, Dittus RS. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004 Apr 14;291(14):1753-62. doi: 10.1001/jama.291.14.1753.
- Background: PubMed 16137350Thomason JW, Shintani A, Peterson JF, Pun BT, Jackson JC, Ely EW. Intensive care unit delirium is an independent predictor of longer hospital stay: a prospective analysis of 261 non-ventilated patients. Crit Care. 2005 Aug;9(4):R375-81. doi: 10.1186/cc3729. Epub 2005 Jun 1.
- Background: PubMed 17102966Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med. 2007 Jan;33(1):66-73. doi: 10.1007/s00134-006-0399-8. Epub 2006 Nov 11.
- Background: PubMed 19745202Pisani MA, Kong SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH. Days of delirium are associated with 1-year mortality in an older intensive care unit population. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1092-7. doi: 10.1164/rccm.200904-0537OC. Epub 2009 Sep 10.
- Background: PubMed 19017895Balas MC, Happ MB, Yang W, Chelluri L, Richmond T. Outcomes Associated With Delirium in Older Patients in Surgical ICUs. Chest. 2009 Jan;135(1):18-25. doi: 10.1378/chest.08-1456. Epub 2008 Nov 18.
- Background: PubMed 15071384Milbrandt EB, Deppen S, Harrison PL, Shintani AK, Speroff T, Stiles RA, Truman B, Bernard GR, Dittus RS, Ely EW. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004 Apr;32(4):955-62. doi: 10.1097/01.ccm.0000119429.16055.92.
- Background: PubMed 18195192Leslie DL, Marcantonio ER, Zhang Y, Leo-Summers L, Inouye SK. One-year health care costs associated with delirium in the elderly population. Arch Intern Med. 2008 Jan 14;168(1):27-32. doi: 10.1001/archinternmed.2007.4.
- Background: PubMed 18978240Devlin JW, Fong JJ, Howard EP, Skrobik Y, McCoy N, Yasuda C, Marshall J. Assessment of delirium in the intensive care unit: nursing practices and perceptions. Am J Crit Care. 2008 Nov;17(6):555-65; quiz 566.
- Background: PubMed 10053175Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, Cooney LM Jr. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999 Mar 4;340(9):669-76. doi: 10.1056/NEJM199903043400901.
- Background: PubMed 19754498Vidan MT, Sanchez E, Alonso M, Montero B, Ortiz J, Serra JA. An intervention integrated into daily clinical practice reduces the incidence of delirium during hospitalization in elderly patients. J Am Geriatr Soc. 2009 Nov;57(11):2029-36. doi: 10.1111/j.1532-5415.2009.02485.x. Epub 2009 Sep 15.
Related trials for Delirium
Recruiting
Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy
Gastric Cancer, Postoperative Delirium
Not yet recruitingObservational study
Comparison of IV Dexmedetomidine Versus Clonidine Versus no Alpha 2 Agonist on Emergency Delirium, PACU Length of Stay and Time to Hospital Discharge in Children Undergoing (Adeno)Tonsillectomy: a Prospective Observational Study
Emergency Delirium, Postoperative Delirium (POD)
Not yet recruiting
Intracuff Dexmedetomidine Versus Alkalinized Lidocaine for Peri-Extubation Cough and Hemodynamic Responses in Elderly Patients
Airway Complication of Anesthesia, Hemodynamic Instability
Not yet recruitingPhase 4
Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine in Ultrasound-Guided Sphenopalatine Ganglion Block for Functional Endoscopic Sinus Surgery
Post Operative Pain, Emergence Agitation
Recruiting
Low Pneumoperitoneum Pressure for Delirium Prevention in Elderly Laparoscopy
Postoperative Delirium (POD), Intracranial Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
KS Simons, drs principal investigator
Jeroen Bosch Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dynamic Light in people with Delirium and Confusion, run by Jeroen Bosch Ziekenhuis at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Oct 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
delirium outcome (time frame: duration of ICU stay(average duration 5 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01274819, which also lists 41 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2013.